Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Shonan iPark was chosen for its globally connected life-science ecosystem, which unites pharmaceutical firms, next-generation medicine developers, AI and digital health innovators, venture capital, and academia
The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Asahi Kasei Life Science covers a broad range of bioprocess products and services
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Subscribe To Our Newsletter & Stay Updated
